)The top 100 stock
market authors
selected for publication in the last week
market authors
selected for publication in the last week
Ketan Desai » Comments » Single Comment
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Those with the largestSee all
increase in followers
in the last week
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
-
Most of Amgen's Epo/Aranesp problems are already factored into the stock price. The future of Amgen is dependent on its pipeline, of which Denosumab (for osteoporosis) is perhaps the most prominent. The competition in the osteoporosis market is not just with Fosamax, but with many other drugs. I will be writing an analysis on this soon.
May 12 07:24 am
|Rating:
0
0
All Comments by Ketan Desai »Amgen: A Random Gamble? [View article]